The ACI is pleased to announce an additional new hire to enable us to meet the demand from CBD companies seeking guidance from our Regulatory Consultancy Team to finalise their novel foods applications.
The UK’s CBD industry is about to hit a crossroads. In just under five months’ time, every CBD company in the country will fall on one side of a new divide: those that have submitted a novel foods application with the country’s Food Standards Agency (FSA), and those that have not. To learn more about these time constraints and just what a CBD toxicology is, Analytical Cannabis spoke with Dr Paul Duffy, the ACI’s lead toxicologist.
To find out more about ACI’s safety studies, the future of CBD in the UK, and what it takes to pass a novel foods assessment, Analytical Cannabis caught up with the ACI’s regulatory lead, Dr Parveen Bhatarah.
The UK’s Food Standards Authority has clarified the data requirements for CBD novel foods applications. This has been welcomed by CBD industry body the ACI as an important step in ensuring the sector’s safety credentials during a time when a cloud of regulatory uncertainty hangs in other parts of Europe.
The ACI welcomes the recent clarifications from The Advisory Council for Novel Foods and Processes (ACNFP) relating to the data requirements for CBD novel foods applications. The ACNFP, who are an advisory committee to the FSA, highlighted the following key points, which emphasise the importance of ACI’s consortium approach to generating this data.
ACI Announce Landmark Safety Study Consortium as Regulator Clarifies Toxicology Requirements for Novel Foods
Today the Association for the Cannabinoid Industry (ACI), in partnership with Advanced Development and Safety Laboratory (ADSL), is announcing the launch of a landmark study with a consortium of CBD companies who are together committed to building a sustainable, safe and fully compliant industry in the UK.
The ACI today welcomes the guidance issued by the Food Standards Agency today which fully validates our consortium approach to generating toxicology safety study data for novel foods applications for CBD in line with the requirements of the Government Committee on Toxicity.
Critical novel foods update: FSA Confirms that Valid CBD Novel Foods Applications Must Include Toxicology Safety Study Data
With just 6 months remaining, for CBD companies to have a valid novel foods application for each of their products, the ACI has received confirmation from the FSA that these dossiers must include toxicology safety study data and literature-based information is not sufficient.
The ACI have received clarification from the FSA on several points concerning novel foods dossier applications that have been raised by our members.